Cargando…

Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system (CNS). It is a leading cause of death among patients with intracranial malignant tumors. GBM exhibits intra- and inter-tumor heterogeneity, leading to drug resistance and eventual tumor recurrence. Conventional treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Weiping, Xu, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347406/
https://www.ncbi.nlm.nih.gov/pubmed/37456742
http://dx.doi.org/10.3389/fphar.2023.1211719
_version_ 1785073542568607744
author Li, Weiping
Xu, Xia
author_facet Li, Weiping
Xu, Xia
author_sort Li, Weiping
collection PubMed
description Glioblastoma (GBM) is the most common malignant tumor of the central nervous system (CNS). It is a leading cause of death among patients with intracranial malignant tumors. GBM exhibits intra- and inter-tumor heterogeneity, leading to drug resistance and eventual tumor recurrence. Conventional treatments for GBM include maximum surgical resection of glioma tissue, temozolomide administration, and radiotherapy, but these methods do not effectively halt cancer progression. Therefore, development of novel methods for the treatment of GBM and identification of new therapeutic targets are urgently required. In recent years, studies have shown that drugs related to mitophagy and mitochondrial apoptosis pathways can promote the death of glioblastoma cells by inducing mitochondrial damage, impairing adenosine triphosphate (ATP) synthesis, and depleting large amounts of ATP. Some studies have also shown that modern nano-drug delivery technology targeting mitochondria can achieve better drug release and deeper tissue penetration, suggesting that mitochondria could be a new target for intervention and therapy. The combination of drugs targeting mitochondrial apoptosis and autophagy pathways with nanotechnology is a promising novel approach for treating GBM.This article reviews the current status of drug therapy for GBM, drugs targeting mitophagy and mitochondrial apoptosis pathways, the potential of mitochondria as a new target for GBM treatment, the latest developments pertaining to GBM treatment, and promising directions for future research.
format Online
Article
Text
id pubmed-10347406
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103474062023-07-15 Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment Li, Weiping Xu, Xia Front Pharmacol Pharmacology Glioblastoma (GBM) is the most common malignant tumor of the central nervous system (CNS). It is a leading cause of death among patients with intracranial malignant tumors. GBM exhibits intra- and inter-tumor heterogeneity, leading to drug resistance and eventual tumor recurrence. Conventional treatments for GBM include maximum surgical resection of glioma tissue, temozolomide administration, and radiotherapy, but these methods do not effectively halt cancer progression. Therefore, development of novel methods for the treatment of GBM and identification of new therapeutic targets are urgently required. In recent years, studies have shown that drugs related to mitophagy and mitochondrial apoptosis pathways can promote the death of glioblastoma cells by inducing mitochondrial damage, impairing adenosine triphosphate (ATP) synthesis, and depleting large amounts of ATP. Some studies have also shown that modern nano-drug delivery technology targeting mitochondria can achieve better drug release and deeper tissue penetration, suggesting that mitochondria could be a new target for intervention and therapy. The combination of drugs targeting mitochondrial apoptosis and autophagy pathways with nanotechnology is a promising novel approach for treating GBM.This article reviews the current status of drug therapy for GBM, drugs targeting mitophagy and mitochondrial apoptosis pathways, the potential of mitochondria as a new target for GBM treatment, the latest developments pertaining to GBM treatment, and promising directions for future research. Frontiers Media S.A. 2023-06-30 /pmc/articles/PMC10347406/ /pubmed/37456742 http://dx.doi.org/10.3389/fphar.2023.1211719 Text en Copyright © 2023 Li and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Weiping
Xu, Xia
Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
title Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
title_full Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
title_fullStr Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
title_full_unstemmed Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
title_short Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
title_sort advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347406/
https://www.ncbi.nlm.nih.gov/pubmed/37456742
http://dx.doi.org/10.3389/fphar.2023.1211719
work_keys_str_mv AT liweiping advancesinmitophagyandmitochondrialapoptosispathwayrelateddrugsinglioblastomatreatment
AT xuxia advancesinmitophagyandmitochondrialapoptosispathwayrelateddrugsinglioblastomatreatment